Does bowel cancer screening actually work?

It is a fair question, and I get asked it often. Screening finds things earlier, but does finding them earlier actually mean fewer people die? Or are we just giving people the same outcome with a longer, more anxious lead up to it?

Until recently my honest answer was that the evidence was strong, but a lot of it came from clinical trials with relatively short follow up. Trials tell you what happens under ideal conditions. They do not always tell you what happens when you roll something out across an entire country, over decades, with real people who forget, delay, or decide not to bother.

A study published in JAMA Network Open on 5 August 2026 is one of the clearest real world answers I have seen. I want to walk through what it found, because it changes the strength of the answer I give patients.

You can read the full study here.

Researchers followed the entire population of the Basque Country in Spain, roughly 2.2 million people, from 2004 to 2024. That is 21 years.

In 2009, Spain introduced an organised bowel screening programme for people aged 50 to 69, using a faecal immunochemical test (FIT) every two years. The same category of test used by New Zealand's National Bowel Screening Programme, and the same category of test True Proactive provides.

Over the study period the researchers recorded 438,134 deaths in total, of which 16,298 were from bowel cancer. They then compared what actually happened with what would have been expected had screening never been introduced.

This is not a small trial. It is a whole population, followed for two decades, through a pandemic, with the data checked against a group who were never invited to screen.

Among people aged 50 to 69, the age standardised bowel cancer death rate fell from 39.7 to 19.8 per 100,000. That is a fall of just over 50%.

When the researchers compared that against the trend the country was on before screening started, the observed death rate was around 46% lower than projected.

Across the whole population, including everyone never invited to screen, deaths fell by 29.6%.

Here is what I find most persuasive, and it is not the headline number.

People under 50 were not invited to screen. They lived in the same country, used the same hospitals, saw the same specialists, and had access to the same cancer treatments over the same 21 years. If the fall in deaths were simply down to better chemotherapy or better surgery, you would expect their numbers to improve too.

They did not significantly change.

The age group being screened halved. The age group not being screened stayed flat. Same country, same medicine, same era. The difference was screening.

Of the cancers found through the programme with staging recorded, 3,464 out of 4,892 were diagnosed at stage I or II. That is roughly seven in ten caught at the early, treatable stages.

This is the mechanism, and it is worth being blunt about why it matters. When bowel cancer is caught early, five year survival can reach more than 90%. When it is found late, survival can be as low as 14%. Same disease. The difference is timing.

The programme also detected 42,071 advanced adenomas. Those are higher risk polyps, the lesions that can quietly turn into cancer given enough years. Finding and removing them is prevention, not just early detection.

The programme began in 2009. Bowel cancer death rates did not start their sustained fall until around 2012.

There was even a small rise in the first few years. That is expected, and it is a known pattern in screening rollouts. When you start looking properly at a population that has never been screened, you find cancers that were already there, sitting undetected. They surface all at once. Then, as the backlog clears and screening moves to catching disease early, the curve bends downward and stays down.

The practical point for anyone reading this is simple. Screening is not a single event that pays off immediately. The benefit accrues from doing it, and continuing to do it.

The disease is the same. The test technology is the same. The main difference is who gets offered it.

New Zealand's National Bowel Screening Programme is free for people aged 58 to 74, and from 30 September 2026 that widens to 56 to 74. It is a good programme and I would encourage anyone eligible to use it.

The Spanish programme in this study began screening at 50.

If you sit outside New Zealand's funded age range, there is no invitation coming, and there is no GP referral needed to screen privately. That is the gap True Proactive was built to fill. Our at home FIT test is analysed at an accredited New Zealand medical laboratory and your result is reviewed by a medical provider, with results usually back within about seven days.

I want to be clear that this sits alongside the national programme, not against it. If you are eligible for the funded test, take it.

I would not be doing my job if I only gave you the good half.

This is an observational study, not a randomised trial. The authors are explicit that it shows association, not proof of cause. It is very strong association, with a sensible comparison group and a plausible mechanism, but it is not the same thing as proof.

It also depended on people actually taking part. Around 70% of invited people returned their test, and more than 91% of those with a positive result went on to have a colonoscopy. A screening test that stays in the drawer, or a positive result that never gets followed up, delivers none of this benefit.

And no stool test is 100%. A negative FIT is genuinely reassuring, but it means no microscopic blood was found at the time of testing. It does not rule out bowel cancer forever. If you develop symptoms, see your GP, regardless of a recent negative result.

1. Screening works, but it works as a habit, not as a one off.
The death rate did not move for three years, then fell for the next decade. The benefit in this study came from a population testing every two years, consistently. If you are screening privately, put it on a yearly cycle and attach it to a date you will not forget, such as a birthday. That is exactly what my wife and I do.

2. If you are outside the funded age range, waiting to become eligible is a decision, not a default.
Spain screened from 50 and halved deaths in that band. New Zealand's funded programme starts at 58, moving to 56 from 30 September 2026. If you are below that and you want to screen, you can, today, without an invitation or a referral. Bowel cancer is the leading cause of cancer death for New Zealanders under 50, and it does not check your age first.

3. The benefit lives in what you do next.
Seven in ten screen detected cancers were caught early because people acted on their results. If your test comes back positive, it is not a diagnosis, it means blood was detected and further investigation is recommended. Here is what happens next. One of our clinicians will contact you to talk it through. Do not sit on it.

If you have been meaning to get around to this, the evidence for doing so has just got stronger. You can order a True Proactive FIT test here, or read more about how our tests work.

If you currently have bowel symptoms, please do not use a screening test as a substitute for assessment. See your GP. There is now a national pathway for people with symptoms, and your GP can access it.

Thanks for reading.

Dr Clive Price

Source: Bujanda L, et al. Organised faecal immunochemical test based screening and colorectal cancer mortality in the Basque Country, Spain, 2004 to 2024. JAMA Network Open. Published 5 August 2026. doi:10.1001/jamanetworkopen.2026.26951

True Proactive tests are screening tools only and do not constitute a medical diagnosis. Always consult your GP.